As expected, significantly decreased percentages of TIGIT+CD226+ CD4 T cells were observed in these patients with DM after treatment compared to those before treatment (28.37% ± 4.064% vs. 18.14 ± 4.578%, p < 0.0001). The gene discussed is CD4; the disease is dermatomyositis.